Novo Holdings A/S's Form 4 filing
Avalyn Pharma Inc. (AVLN) · filed May 5, 2026
- Accession no.
- 0001388325-26-000021
- Filed
- May 5, 2026
- Trade date
- May 1, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 5 derivative transactions. Open-market purchases total $10.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Novo Holdings A/SCIK 0001388325 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Voting Common Stock | CConversionAcquired | +3,327,734 | –F1 | – | 3,327,734 | Direct | |
| May 1, 2026 | Voting Common Stock | PPurchaseAcquired | +555,555 | $18.00 | +$9,999,990 | 3,883,289 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Voting Common Stock | CConversionDisposed | −935,466 | $0.00 | $0 | 0 | Direct | |
| May 1, 2026 | Voting Common Stock | CConversionDisposed | −103,232 | $0.00 | $0 | 0 | Direct | |
| May 1, 2026 | Voting Common Stock | CConversionDisposed | −1,345,997 | $0.00 | $0 | 0 | Direct | |
| May 1, 2026 | Voting Common Stock | CConversionDisposed | −290,390 | $0.00 | $0 | 0 | Direct | |
| May 1, 2026 | Voting Common Stock | CConversionDisposed | −652,649 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date.
Referenced by the price of 1 transaction in Table I.